Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

被引:12
|
作者
Zhou, Juan [1 ]
Ye, Yuanxin [1 ]
Zeng, Shugen [1 ]
Zhou, Yi [1 ]
Mao, Zhigang [1 ]
Song, Xingbo [1 ]
Ying, Binwu [1 ]
Lu, Xiaojun [1 ]
Jiang, Hong [1 ]
Wang, Lanlan [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu 610064, Sichuan Provinc, Peoples R China
来源
PLOS ONE | 2013年 / 8卷 / 02期
基金
中国国家自然科学基金;
关键词
CHRONIC MYELOPROLIFERATIVE DISORDERS; TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; CLINICAL-SIGNIFICANCE; JAK2(V617F); ACTIVATION; JAK2V617F; MYELOFIBROSIS; GRANULOCYTES;
D O I
10.1371/journal.pone.0057856
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients' hemogram variation remains not clear. Methods: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR). Results: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P-25-P-75): 45.02%(35.12%-54.22%)] than in essential thrombocythemia (ET) patients [median(P-25-P-75): 28.23%(17.77%-41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = -0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts. Conclusions: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] The JAK2 V617F mutation in patients with cerebral venous thrombosis
    Passamonti, S. M.
    Biguzzi, E.
    Cazzola, M.
    Franchi, F.
    Gianniello, F.
    Bucciarelli, P.
    Pietra, D.
    Mannucci, P. M.
    Martinelli, I.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (06) : 998 - 1003
  • [2] JAK2 (V617F) mutation in healthy individuals
    Passamonti, Francesco
    Rumi, Elisa
    Pietra, Daniela
    Lazzarino, Mario
    Cazzola, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 678 - 679
  • [3] Is the JAK2 V617F Mutation a Hallmark for Different Forms of Thrombosis?
    Zerjavic, Katja
    Zagradisnik, Boris
    Herodez, Spela Stangler
    Lokar, Lidija
    Krasevac, Marjana Glaser
    Vokac, Nadja Kokalj
    ACTA HAEMATOLOGICA, 2010, 124 (01) : 49 - 56
  • [4] Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders
    Sazawal, Sudha
    Bajaj, Jyoti
    Chikkara, Sunita
    Jain, Sonal
    Bhargava, Rahul
    Mahapatra, Manoranjan
    Saxena, Renu
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2010, 132 (04) : 423 - 427
  • [5] Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients
    Muendlein, Axel
    Gasser, Klaus
    Kinz, Elena
    Stark, Nicole
    Leiherer, Andreas
    Rein, Philipp
    Saely, Christoph H.
    Grallert, Harald
    Peters, Annette
    Drexel, Heinz
    Lang, Alois H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 295 - 301
  • [6] The V617F JAK2 mutation and the myeloproliferative disorders
    Percy, MJ
    McMullin, MF
    HEMATOLOGICAL ONCOLOGY, 2005, 23 (3-4) : 91 - 93
  • [7] Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease
    Muendlein, Axel
    Kinz, Elena
    Gasser, Klaus
    Leiherer, Andreas
    Rein, Philipp
    Saely, Christoph H.
    Grallert, Harald
    Peters, Annette
    Fraunberger, Peter
    Drexel, Heinz
    Lang, Alois H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (01) : E17 - E21
  • [8] Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms
    Chadi, Soumaya
    Dhaouadi, Tarak
    Sfar, Imen
    Baccouche, Hela
    Nabli, Rym
    Ben Romdhane, Neila
    Ben Abdallah, Taieb
    Gorgi, Yousr
    EUROPEAN JOURNAL OF INFLAMMATION, 2021, 19
  • [9] Absence of JAK2 V617F mutation in thalassemia intermedia patients
    Taher, Ali
    Shammaa, Dina
    Bazarbachi, Ali
    Itani, Doha
    Zaatari, Ghazi
    Greige, Layal
    Otrock, Zaher K.
    Mahfouz, Rami A. R.
    MOLECULAR BIOLOGY REPORTS, 2009, 36 (06) : 1555 - 1557
  • [10] Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
    Basquiera, Ana L.
    Soria, Nestor W.
    Ryser, Ricardo
    Salguero, Miriam
    Moiraghi, Beatriz
    Sackmann, Federico
    Sturich, Ana G.
    Borello, Adriana
    Berretta, Adriana
    Bonafe, Miriam
    Moreno Barral, Jose
    Palazzo, Emilio D.
    Garcia, Juan J.
    HEMATOLOGY, 2009, 14 (06) : 323 - 330